Investor · 1 deal

University of Otago

Dunedin

Disclosed deals

Every published round University of Otago took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.

Company	Stage	Announced	Amount	Role	Alongside	Sources
Amaroq Therapeutics	Unnamed stage	8 Jul 2021	$14m	Participant	Brandon Capital Otago Innovation Ltd NZ Innovation Booster Cure Kids Ventures	Brandon Capital portfolio (Mon 4 Apr 2022), Brandon BioCatalyst portfolio (Mon 4 Apr 2022), Brandon BioCatalyst portfolio (Thu 8 Jul 2021), Brandon Capital portfolio (Thu 8 Jul 2021), Brandon Capital portfolio (Thu 8 Jul 2021), Brandon BioCatalyst portfolio (Thu 8 Jul 2021)

Portfolio

Companies University of Otago has backed in a published round, and companies whose existing shares it bought off another holder.

Company	What it does	First invested	Rounds	Led
Amaroq Therapeutics		8 Jul 2021	1	0

Funds

Fund closes reported for University of Otago, as distinct from the investments it has made.

Fund	Announced	Committed	Target	Close	Sources
No fund closes recorded for University of Otago yet.

Portfolio companies acquired

Companies University of Otago has backed that another company then bought. An exit for the holding, not a deal University of Otago did.

Company	Bought by	Kind	Announced	Price
No portfolio company of University of Otago is recorded as having been acquired.

Coverage

Stories naming University of Otago. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Unnamed stage

Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa

Vaxxas reports positive Phase I results for its needle-free skin-patch delivery of a measles-rubella vaccine, with Gates Foundation grant funding and a planned PATH-sponsored Phase I/II trial in The Gambia.

Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au

Seed

Why We Invested in Sahha AI

Aura Ventures explains why it led Sahha's seed round, citing the health-data gap, Sahha's behavioural-health API, its neuroscience-led team and its University of Otago research partnership.

Aura Ventures Mon 20 Nov 2023 Sahha University of Otago Antler Australia Aura Ventures

Exit / M&A

Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board

Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.

2 deals

$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments

Brandon Capital led a NZ$14 million investment in Amaroq Therapeutics, a University of Otago spinout developing RNA cancer therapies, with three co-investors and a Callaghan Innovation repayable grant supporting the deal.

Brandon Capital portfolio Thu 8 Jul 2021 Amaroq Therapeutics Booster Financial Services Mana Communications Medical Research Commercialisation Fund (MRCF)Royal Society Te Apārangi Wellington UniVentures Brandon Capital Callaghan Innovation Cure Kids Ventures NZ Innovation Booster Otago Innovation Ltd University of Otago Caleb Hulme-Moir David Christensen Duncan Mackintosh Dr Sarah Diermeier

Something wrong? Tell us